复星医药授予Sitala海外开发权 加速创新药FXS6837全球化布局

Core Viewpoint - Fosun Pharma (600196)(02196) announced a licensing agreement with Sitala for the development, production, and commercialization of FXS6837 and related products in a global scope excluding China (including Hong Kong, Macau, and Taiwan) [1] Group 1 - The licensing agreement allows Fosun Pharma's subsidiary to obtain rights for human and animal disease diagnostics and treatments [1] - Fosun Pharma's subsidiary can acquire shares of Sitala valued at $5 million at zero cost based on this licensing arrangement [1] - This collaboration is expected to accelerate the clinical development and commercialization of licensed products globally and expand the group's innovative product portfolio overseas [1]